Sequoia Financial Advisors LLC Has $1.01 Million Position in Sanofi (NASDAQ:SNY)

Sequoia Financial Advisors LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 2.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 21,003 shares of the company’s stock after purchasing an additional 425 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,013,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Abel Hall LLC increased its stake in shares of Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after buying an additional 194 shares in the last quarter. Keudell Morrison Wealth Management increased its stake in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after buying an additional 217 shares in the last quarter. Bailard Inc. increased its stake in shares of Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after buying an additional 220 shares in the last quarter. Old Port Advisors increased its stake in shares of Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after buying an additional 232 shares in the last quarter. Finally, ORG Partners LLC increased its stake in shares of Sanofi by 17.7% in the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock valued at $81,000 after buying an additional 253 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY stock opened at $57.75 on Monday. The stock has a 50-day moving average price of $53.65 and a 200 day moving average price of $52.81. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a market cap of $146.56 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 12 month low of $45.22 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts expect that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.